X4 Pharmaceuticals, Inc.

NasdaqCM:XFOR Stock Report

Market Cap: US$349.7m

X4 Pharmaceuticals Valuation

Is XFOR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of XFOR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate XFOR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate XFOR's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for XFOR?

Key metric: As XFOR is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for XFOR. This is calculated by dividing XFOR's market cap by their current revenue.
What is XFOR's PS Ratio?
PS Ratio10x
SalesUS$33.98m
Market CapUS$349.75m

Price to Sales Ratio vs Peers

How does XFOR's PS Ratio compare to its peers?

The above table shows the PS ratio for XFOR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average6.2x
KROS Keros Therapeutics
2.3x-23.16%US$564.5m
IVVD Invivyd
11.6x39.78%US$575.8m
BDTX Black Diamond Therapeutics
2x7.98%US$138.4m
KURA Kura Oncology
8.6x39.86%US$898.5m
XFOR X4 Pharmaceuticals
10x52.26%US$349.7m

Price-To-Sales vs Peers: XFOR is expensive based on its Price-To-Sales Ratio (10x) compared to the peer average (6.1x).

Price to Sales Ratio vs Industry

How does XFOR's PS Ratio compare vs other companies in the US Biotechs Industry?

121 CompaniesPrice / SalesEstimated GrowthMarket Cap
BIIB Biogen
2.6x-1.44%US$25.82b
BMRN BioMarin Pharmaceutical
3.7x5.77%US$11.42b
PTCT PTC Therapeutics
3.5x1.28%US$6.10b
ALKS Alkermes
3.1x8.02%US$4.62b
XFOR 10.0xIndustry Avg. 11.7xNo. of Companies121PS01632486480+
121 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: XFOR is good value based on its Price-To-Sales Ratio (10x) compared to the US Biotechs industry average (11.9x).

Price to Sales Ratio vs Fair Ratio

What is XFOR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

XFOR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio10x
Fair PS Ratio18.9x

Price-To-Sales vs Fair Ratio: XFOR is good value based on its Price-To-Sales Ratio (10x) compared to the estimated Fair Price-To-Sales Ratio (18.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst XFOR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$3.89
US$8.00
+105.66%
45.93%US$13.00US$4.00n/a4
Dec ’26US$3.15
US$7.38
+134.13%
47.31%US$13.00US$4.00n/a4
Nov ’26US$4.04
US$8.70
+115.35%
50.31%US$14.00US$3.50n/a5
Oct ’26US$3.62
US$8.70
+140.33%
50.31%US$14.00US$3.50n/a5
Sep ’26US$3.76
US$19.75
+425.97%
126.73%US$75.00US$3.50n/a6
Aug ’26US$1.60
US$42.67
+2,566.67%
97.33%US$120.00US$7.00n/a6
Jul ’26US$1.86
US$42.67
+2,193.91%
97.33%US$120.00US$7.00n/a6
Jun ’26US$3.40
US$42.67
+1,154.90%
97.33%US$120.00US$7.00n/a6
May ’26US$3.75
US$65.00
+1,633.33%
43.51%US$120.00US$30.00n/a6
Apr ’26US$6.65
US$80.00
+1,102.83%
29.97%US$120.00US$45.00n/a6
Mar ’26US$11.85
US$93.75
+690.94%
32.58%US$120.00US$45.00n/a6
Feb ’26US$21.00
US$93.75
+346.36%
32.58%US$120.00US$45.00n/a6
Jan ’26US$22.01
US$91.45
+315.53%
32.42%US$120.00US$45.00US$4.006
Dec ’25US$11.79
US$80.53
+583.02%
47.60%US$120.00US$15.00US$3.157
Nov ’25US$15.57
US$121.37
+679.52%
35.07%US$150.00US$30.00US$4.047
Oct ’25US$19.06
US$121.37
+536.92%
35.07%US$150.00US$30.00US$3.627
Sep ’25US$21.00
US$121.37
+477.96%
35.07%US$150.00US$30.00US$3.767
Aug ’25US$23.28
US$123.51
+430.56%
35.86%US$165.00US$30.00US$1.607
Jul ’25US$17.68
US$123.51
+598.53%
35.86%US$165.00US$30.00US$1.867
Jun ’25US$30.30
US$123.51
+307.64%
35.86%US$165.00US$30.00US$3.407
May ’25US$33.15
US$123.51
+272.59%
35.86%US$165.00US$30.00US$3.757
Apr ’25US$42.30
US$98.06
+131.81%
36.60%US$150.00US$30.00US$6.657
Mar ’25US$30.30
US$97.93
+223.20%
36.68%US$150.00US$30.00US$11.857
Feb ’25US$25.20
US$97.93
+288.56%
36.68%US$150.00US$30.00US$21.007
Jan ’25US$25.16
US$96.86
+285.04%
37.56%US$150.00US$30.00US$22.017
US$8
Fair Value
51.4% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/02 17:09
End of Day Share Price 2026/01/02 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

X4 Pharmaceuticals, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Leah Rush CannBrookline Capital Markets
Arlinda LeeCanaccord Genuity
Swayampakula RamakanthH.C. Wainwright & Co.